scholarly journals Expression of retinoic acid receptor proteins in basal cell carcinomas: an immunohistochemical analysis.

1996 ◽  
Vol 44 (12) ◽  
pp. 1415-1420 ◽  
Author(s):  
J Kamradt ◽  
J Reichrath
Keyword(s):  
Retinoic Acid ◽  
Basal Cell ◽  
Retinoic Acid Receptor ◽  
Immunohistochemical Analysis ◽  
Ki 67 ◽  
Weak Staining ◽  
Basal Cell Carcinomas ◽  
Acid Metabolites ◽  
Peripheral Cells ◽  
Labeling Pattern

We analyzed immunohistochemically the expression of RAR proteins in basal cell carcinomas (BCCs; n = 15) in situ. The labeling pattern for the different types of RARs was compared with the staining pattern of the proliferation marker Ki-67 in the same tumors. We found strong immunoreactivity for RAR-alpha and moderate immunoreactivity for RAR-gamma in all BCCs analyzed, whereas no or very weak staining for RAR-beta protein was detected. In contrast to RAR-gamma, which revealed no or only marginal differences in staining intensities, RAR-alpha immunoreactivity was consistently stronger in BCCs compared to adjacent unaffected epidermis. In general, labeling of BCCs for RAR-alpha and RAR-gamma was pronounced in cells of the palisade and peripheral cells, whereas staining in the center of the tumors was heterogeneous. Eleven of the 15 BCCs analyzed revealed no visual correlation in comparing labeling patterns for RAR-alpha and RAR-gamma with the labeling pattern for Ki-67. In four specimens, expression of RAR-alpha, RAR-gamma, and Ki-67 proteins was confined to peripheral tumor cells. Our findings indicate that (a) RAR-alpha and RAR-gamma proteins are, in contrast to RAR-beta, strongly expressed in BCCs; (b) expression of RAR-alpha is upregulated in BCCs compared to keratinocytes of uninvolved epidermis; and (c) BCCs may be targets for potentially preventive or therapeutic treatment with RAR-alpha- or RAR-gamma-selective retinoic acid metabolites.

scholarly journals Prostate Basal Cell Carcinoma: A Case Report

2018 ◽  
Vol 11 (1) ◽  
pp. 138-142 ◽  
Author(s):  
Sahoko Ninomiya ◽  
Takashi Kawahara ◽  
Hiromichi Iwashita ◽  
Genta Iwamoto ◽  
Daiji Takamoto ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Immunohistochemical Analysis ◽  
Pathological Examination ◽  
Ki 67 ◽  
Prostate Hyperplasia ◽  
Atypical Cells ◽  
Prostate Cancers ◽  
Benign Prostate

Prostate basal cell carcinoma (PBCC) accounts for 0.01% of all prostate cancers. A 68-year-old man complained of dysuria for 5 years on his initial visit. His PSA level was 3.87 ng/mL. Due to a diagnosis of benign prostate hyperplasia, he underwent transurethral resection of the prostate. A pathological examination revealed that basal cell-like atypical cells made alveolar with palisadal layout. Immunohistochemical analysis showed positive 34β12, P63, and Ki-67. Based on these findings, PBCC was diagnosed. Then, we performed radical prostatectomy. He was free from recurrence 22 months after the operation. We herein report an extremely rare case of PBCC.

scholarly journals Rapid diagnosis of acute promyelocytic leukemia by immunohistochemical localization of PML/RAR-alpha protein

Blood ◽  
1995 ◽  
Vol 86 (3) ◽  
pp. 862-867 ◽  
Author(s):  
JA Dyck ◽  
RP Jr Warrell ◽  
RM Evans ◽  
WH Jr Miller
Keyword(s):  
Retinoic Acid ◽  
Acute Promyelocytic Leukemia ◽  
Retinoic Acid Receptor ◽  
Immunohistochemical Localization ◽  
Promyelocytic Leukemia ◽  
Nuclear Bodies ◽  
Myelogenous Leukemia ◽  
Molecular Rearrangement ◽  
Labeling Pattern ◽  
In Cells

Acute promyelocytic leukemia (APL) is characterized by a consistent chromosomal aberration that fuses the retinoic acid receptor alpha (RAR alpha) gene with the novel gene PML, resulting in the expression of a PML/RAR-alpha fusion protein. Immunohistochemical examination of APL cells shows a unique abnormal distribution of anti-PML and anti-RAR alpha antibody labeling. The PML labeling pattern observed in normal cells consists of 5 to 10 discrete spherical nuclear bodies called PODs (for “PML oncogenic domains”), whereas that of APL consists of a smaller and far more numerous speckled pattern. We examined malignant cells from patients with a variety of hematopoietic cancers by immunohistochemistry (IH) and found this abnormal PML pattern expressed in cells from patients with t(15;17)-associated leukemia but not in patients with other neoplastic disorders. IH results agreed with reverse transcription polymerase chain reaction for PML/RAR-alpha in 31 of 32 patients with acute myelogenous leukemia, including 5 of 5 patients in whom the initial clinical diagnosis of APL was not supported by cytogenetics, molecular tests, or response to all-trans retinoic acid (RA). Cells from patients with APL were examined during the course of retinoid therapy and at the time of complete remission and relapse. Reorganization of the PML labeling into PODs with normal appearance was observed in cells from patients who received RA. IH showed primarily normal PML staining during clinical remission, although the APL-specific labeling pattern was again seen in cells taken from patients at the time of relapse. Thus, IH provides an independent assay for the presence and expression of the molecular rearrangement of APL. The relative ease and speed of detecting the APL- specific PML labeling pattern should make IH a useful diagnostic tool to guide specific therapy of APL, and establish a direct assay for PML/RAR-alpha protein expression and localization in individual patient cells.

Ki-67 antigen expression and growth pattern of basal cell carcinomas

1993 ◽  
Vol 285 (5) ◽  
pp. 291-295 ◽  
Author(s):  
H. -P. Baum ◽  
I. Meurer ◽  
G. Unteregger
Keyword(s):  
Basal Cell ◽  
Growth Pattern ◽  
Antigen Expression ◽  
Ki 67 ◽  
Basal Cell Carcinomas
Sign in / Sign up

Export Citation Format

Share Document